MEA Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Description

List of Tables

Middle East and Africa breast cancer diagnostics market is projected to register a CAGR of 7.1% from 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Middle East and Africa Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Middle East and Africa breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the Middle East and Africa breast cancer diagnostics market are:

Cepheid

BIOMERIEUX

Exact Sciences Corporation

Biocept, Inc.

Abacus ALS

1 INTRODUCTION 48

1.1 OBJECTIVES OF THE STUDY 48
1.2 MARKET DEFINITION 48
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET 48
1.4 CURRENCY AND PRICING 50
1.5 LIMITATIONS 50
1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

2.1 MARKETS COVERED 54
2.2 GEOGRAPHICAL SCOPE 55
2.3 YEARS CONSIDERED FOR THE STUDY 56
2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
2.6 MULTIVARIATE MODELLING 61
2.7 MARKET END USER COVERAGE GRID 62
2.8 TEST TYPE LIFELINE CURVE 63
2.9 DBMR MARKET POSITION GRID 64
2.10 VENDOR SHARE ANALYSIS 65
2.11 SECONDARY SOURCES 66
2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

4.1 PESTEL ANALYSIS 70
4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

8.1 DRIVERS 78
- 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
- 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
- 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
- 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
8.2 RESTRAINTS 80
- 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
- 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
8.3 OPPORTUNITIES 81
- 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
- 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
- 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
8.4 CHALLENGES 82
- 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
- 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

9.1 OVERVIEW 85
9.2 IMAGING 88
- 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
  - 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
  - 9.2.1.2 ANALOG MAMMOGRAPHY 90
  - 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
  - 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
  - 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
  - 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
  - 9.2.1.7 OTHERS 90
- 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
  - 9.2.2.1 OPTICAL IMAGING 91
  - 9.2.2.2 BREAST ULTRASOUND 91
  - 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
  - 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
  - 9.2.2.5 BREAST THERMOGRAPHY 92
- 9.2.3 BIOPSY 92
  - 9.2.3.1 SURGICAL BIOPSY 93
  - 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
  - 9.2.3.3 CORE NEEDLE BIOPSY 93
  - 9.2.3.4 IMAGE-GUIDED BIOPSY 93
  - 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
- 9.2.4 GENOMIC TEST 94
  - 9.2.4.1 MOLECULAR TESTING 95
    - 9.2.4.1.1 PD-L1 96
    - 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
    - 9.2.4.1.3 NTRK GENE FUSIONS 96
    - 9.2.4.1.4 PI3KCA GENE MUTATION 96
  - 9.2.4.2 MAMMAPRINT 96
  - 9.2.4.3 ONCOTYPE DX 96
  - 9.2.4.4 OTHERS 96
9.3 BLOOD TEST 97
9.4 OTHERS 98

10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

10.1 OVERVIEW 100
10.2 INVASIVE DUCTAL CARCINOMA 103
10.3 DUCTAL CARCINOMA IN SITU 103
10.4 INFLAMMATORY BREAST CANCER 104
10.5 METASTATIC BREAST CANCER 105

11 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

11.1 OVERVIEW 107
11.2 HOSPITALS 109
11.3 DIAGNOSTICS CENTERS 110
11.4 CLINICS 111
11.5 RESEARCH & ACADEMIC INSTITUTES 111
11.6 OTHERS 112

12 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

12.1 OVERVIEW 115
12.2 DIRECT TENDER 118
12.3 RETAIL SALES 118
12.4 OTHERS 119

13 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

13.1 MIDDLE EAST AND AFRICA 121
- 13.1.1 EGYPT 130
- 13.1.2 SOUTH AFRICA 136
- 13.1.3 ISRAEL 142
- 13.1.4 SAUDI ARABIA 148
- 13.1.5 UAE 154
- 13.1.6 REST OF MIDDLE EAST AND AFRICA 160

14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 161

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 161

15 SWOT ANALYSIS 162

16 COMPANY PROFILE 163

16.1 HOLOGIC, INC. 163
- 16.1.1 COMPANY SNAPSHOT 163
- 16.1.2 REVENUE ANALYSIS 163
- 16.1.3 COMPANY SHARE ANALYSIS 164
- 16.1.4 PRODUCT PORTFOLIO 164
- 16.1.5 RECENT DEVELOPMENTS 165
16.2 SIEMENS HEALTHCARE GMBH 166
- 16.2.1 COMPANY SNAPSHOT 166
- 16.2.2 REVENUE ANALYSIS 167
- 16.2.3 COMPANY SHARE ANALYSIS 167
- 16.2.4 PRODUCT PORTFOLIO 168
- 16.2.5 RECENT DEVELOPMENTS 168
16.3 F. HOFFMANN- LA ROCHE LTD 169
- 16.3.1 COMPANY SNAPSHOT 169
- 16.3.2 REVENUE ANALYSIS 169
- 16.3.3 COMPANY SHARE ANALYSIS 170
- 16.3.4 PRODUCT PORTFOLIO 170
- 16.3.5 RECENT DEVELOPMENTS 171
16.4 KONINKLIJKE PHILIPS N.V. 172
- 16.4.1 COMPANY SNAPSHOT 172
- 16.4.2 REVENUE ANALYSIS 172
- 16.4.3 COMPANY SHARE ANALYSIS 173
- 16.4.4 PRODUCT PORTFOLIO 173
- 16.4.5 RECENT DEVELOPMENTS 174
16.5 ABBOTT 175
- 16.5.1 COMPANY SNAPSHOT 175
- 16.5.2 REVENUE ANALYSIS 175
- 16.5.3 COMPANY SHARE ANALYSIS 176
- 16.5.4 PRODUCT PORTFOLIO 176
- 16.5.5 RECENT DEVELOPMENTS 176
16.6 ABACUS ALS 177
- 16.6.1 COMPANY SNAPSHOT 177
- 16.6.2 PRODUCT PORTFOLIO 177
- 16.6.3 RECENT DEVELOPMENTS 177
16.7 BD 178
- 16.7.1 COMPANY SNAPSHOT 178
- 16.7.2 REVENUE ANALYSIS 178
- 16.7.3 COMPANY SHARE ANALYSIS 179
- 16.7.4 PRODUCT PORTFOLIO 179
- 16.7.5 RECENT DEVELOPMENTS 179
16.8 BIOCEPT, INC. 180
- 16.8.1 COMPANY SNAPSHOT 180
- 16.8.2 REVENUE ANALYSIS 180
- 16.8.3 PRODUCT PORTFOLIO 181
- 16.8.4 RECENT DEVELOPMENTS 181
16.9 BIOMERIEUX 182
- 16.9.1 COMPANY SNAPSHOT 182
- 16.9.2 REVENUE ANALYSIS 182
- 16.9.3 PRODUCT PORTFOLIO 183
- 16.9.4 RECENT DEVELOPMENTS 183
16.10 BIO-RAD LABORATORIES, INC. 184
- 16.10.1 COMPANY SNAPSHOT 184
- 16.10.2 REVENUE ANALYSIS 184
- 16.10.3 PRODUCT PORTFOLIO 185
- 16.10.4 RECENT DEVELOPMENT 185
16.11 CEPHEID 186
- 16.11.1 COMPANY SNAPSHOT 186
- 16.11.2 REVENUE ANALYSIS 186
- 16.11.3 PRODUCT PORTFOLIO 187
- 16.11.4 RECENT DEVELOPMENT 187
16.12 EXACT SCIENCES CORPORATION 188
- 16.12.1 COMPANY SNAPSHOT 188
- 16.12.2 REVENUE ANALYSIS 188
- 16.12.3 COMPANY SHARE ANALYSIS 189
- 16.12.4 PRODUCT PORTFOLIO 189
- 16.12.5 RECENT DEVELOPMENTS 190
16.13 FUJIFILM CORPORATION 191
- 16.13.1 COMPANY SNAPSHOT 191
- 16.13.2 REVENUE ANALYSIS 191
- 16.13.3 PRODUCT PORTFOLIO 192
- 16.13.4 RECENT DEVELOPMENT 192
16.14 GENERAL ELECTRIC 193
- 16.14.1 COMPANY SNAPSHOT 193
- 16.14.2 REVENUE ANALYSIS 193
- 16.14.3 PRODUCT PORTFOLIO 194
- 16.14.4 RECENT DEVELOPMENTS 194
16.15 ILLUMINA, INC. 195
- 16.15.1 COMPANY SNAPSHOT 195
- 16.15.2 REVENUE ANALYSIS 195
- 16.15.3 PRODUCT PORTFOLIO 196
- 16.15.4 RECENT DEVELOPMENTS 196
16.16 MYRIAD GENETICS, INC. 197
- 16.16.1 COMPANY SNAPSHOT 197
- 16.16.2 REVENUE ANALYSIS 197
- 16.16.3 PRODUCT PORTFOLIO 198
- 16.16.4 RECENT DEVELOPMENT 198
16.17 NANOSTRING. 199
- 16.17.1 COMPANY SNAPSHOT 199
- 16.17.2 REVENUE ANALYSIS 199
- 16.17.3 PRODUCT PORTFOLIO 200
- 16.17.4 RECENT DEVELOPMENT 200
- 16.17.5 RECENT DEVELOPMENT 200
16.18 ONCOSTEM. 201
- 16.18.1 COMPANY SNAPSHOT 201
- 16.18.2 PRODUCT PORTFOLIO 201
- 16.18.3 RECENT DEVELOPMENT 201
16.19 PROVISTA DIAGNOSTICS. 202
- 16.19.1 COMPANY SNAPSHOT 202
- 16.19.2 PRODUCT PORTFOLIO 202
- 16.19.3 RECENT DEVELOPMENT 202
16.20 THERMO FISHER SCIENTIFIC INC. 203
- 16.20.1 COMPANY SNAPSHOT 203
- 16.20.2 REVENUE ANALYSIS 203
- 16.20.3 PRODUCT PORTFOLIO 204
- 16.20.4 RECENT DEVELOPMENT 204

17 QUESTIONNAIRE 205

18 RELATED REPORTS 208

LIST OF TABLES

TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 44
TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 44
TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 44
TABLE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 59
TABLE 5 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 6 MIDDLE EAST & AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 60
TABLE 7 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 61
TABLE 8 MIDDLE EAST & AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 61
TABLE 9 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 63
TABLE 10 MIDDLE EAST & AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 63
TABLE 11 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 64
TABLE 12 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
TABLE 13 MIDDLE EAST & AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 65
TABLE 14 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 66
TABLE 15 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
TABLE 16 MIDDLE EAST & AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 67
TABLE 17 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 67
TABLE 18 MIDDLE EAST & AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 68
TABLE 19 MIDDLE EAST & AFRICA BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 74
TABLE 22 MIDDLE EAST & AFRICA INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 23 MIDDLE EAST & AFRICA DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 76
TABLE 24 MIDDLE EAST & AFRICA INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 25 MIDDLE EAST & AFRICA METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 81
TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 28 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
TABLE 29 MIDDLE EAST & AFRICA CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 83
TABLE 30 MIDDLE EAST & AFRICA RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 32 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 89
TABLE 33 MIDDLE EAST & AFRICA DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 34 MIDDLE EAST & AFRICA RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 36 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 97
TABLE 37 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 38 MIDDLE EAST AND AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 97
TABLE 39 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 40 MIDDLE EAST AND AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 98
TABLE 41 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 42 MIDDLE EAST AND AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 99
TABLE 43 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 44 MIDDLE EAST AND AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 99
TABLE 45 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 99
TABLE 46 MIDDLE EAST AND AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 100
TABLE 47 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 48 MIDDLE EAST AND AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 100
TABLE 49 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 100
TABLE 50 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 101
TABLE 51 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 101
TABLE 52 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 53 EGYPT IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 54 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 55 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 103
TABLE 56 EGYPT IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 103
TABLE 57 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
TABLE 58 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 104
TABLE 59 EGYPT NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
TABLE 60 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 61 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 104
TABLE 62 EGYPT BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 63 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 64 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 105
TABLE 65 EGYPT GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
TABLE 66 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
TABLE 67 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 106
TABLE 68 EGYPT MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 106
TABLE 69 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 106
TABLE 70 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
TABLE 71 EGYPT BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 107
TABLE 72 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 73 SOUTH AFRICA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 74 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 75 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
TABLE 76 SOUTH AFRICA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
TABLE 77 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 109
TABLE 78 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
TABLE 79 SOUTH AFRICA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
TABLE 80 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 81 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
TABLE 82 SOUTH AFRICA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
TABLE 83 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 84 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 111
TABLE 85 SOUTH AFRICA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
TABLE 86 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 111
TABLE 87 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 112
TABLE 88 SOUTH AFRICA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 112
TABLE 89 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 112
TABLE 90 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 112
TABLE 91 SOUTH AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 113
TABLE 92 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 93 ISRAEL IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 94 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 95 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
TABLE 96 ISRAEL IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
TABLE 97 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
TABLE 98 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
TABLE 99 ISRAEL NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
TABLE 100 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 101 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
TABLE 102 ISRAEL BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
TABLE 103 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
TABLE 104 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 117
TABLE 105 ISRAEL GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
TABLE 106 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 117
TABLE 107 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 118
TABLE 108 ISRAEL MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 118
TABLE 109 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 110 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 118
TABLE 111 ISRAEL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 119
TABLE 112 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 113 SAUDI ARABIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 114 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
TABLE 115 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
TABLE 116 SAUDI ARABIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 121
TABLE 117 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
TABLE 118 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
TABLE 119 SAUDI ARABIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
TABLE 120 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
TABLE 121 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
TABLE 122 SAUDI ARABIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
TABLE 123 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
TABLE 124 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 123
TABLE 125 SAUDI ARABIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
TABLE 126 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 123
TABLE 127 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 124
TABLE 128 SAUDI ARABIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 124
TABLE 129 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 124
TABLE 130 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 124
TABLE 131 SAUDI ARABIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 125
TABLE 132 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 133 UAE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 134 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
TABLE 135 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
TABLE 136 UAE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 127
TABLE 137 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
TABLE 138 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
TABLE 139 UAE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
TABLE 140 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
TABLE 141 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
TABLE 142 UAE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
TABLE 143 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 144 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 129
TABLE 145 UAE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
TABLE 146 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 129
TABLE 147 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 130
TABLE 148 UAE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 130
TABLE 149 UAE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 130
TABLE 150 UAE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 151 UAE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 131
TABLE 152 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132

LIST OF FIGURES

FIGURE 1 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 25
FIGURE 2 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 28
FIGURE 3 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 29
FIGURE 4 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 30
FIGURE 5 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 30
FIGURE 6 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 31
FIGURE 7 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 33
FIGURE 8 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 35
FIGURE 9 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 36
FIGURE 10 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 39
FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 40
FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 40
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET 48
FIGURE 14 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 56
FIGURE 15 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 57
FIGURE 16 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 57
FIGURE 17 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 58
FIGURE 18 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 71
FIGURE 19 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 72
FIGURE 20 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 72
FIGURE 21 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 73
FIGURE 22 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 78
FIGURE 23 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 79
FIGURE 24 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 79
FIGURE 25 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 80
FIGURE 26 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 86
FIGURE 27 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 87
FIGURE 28 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 87
FIGURE 29 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 88
FIGURE 30 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 93
FIGURE 31 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 94
FIGURE 32 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 94
FIGURE 33 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 95
FIGURE 34 MIDDLE EAST AND AFRICA BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 95
FIGURE 35 MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 132